In this context, glucagon-like peptide-1 receptor (GLP-1R) agonists have been increasingly used in the treatment of pediatric obesity, with evidence supporting their efficacy in reducing body weight, BMI, and improving glycemic control, although gastrointestinal side effects, such as nausea, are common
It undermines evidence-based care, discourages people from seeking treatment, and drives up costs for employers and health plans
Also, the rare, but serious, side effect of diabetic ketoacidosis can hinder their use particularly in those with longer diabetes duration and limited beta-cell reserves
Thresholds for meaningful deterioration were smaller than those for improvement, suggesting less change is needed to identify meaningful deterioration than improvement in ADHD
Data were analyzed using a two-tailed Student's t-test, one-way analysis of variance (ANOVA), or two-way ANOVA, followed by Dunnett's or idk's multiple comparison test